



Sample content

Breast Cancer

Disease Landscape & Forecast

Published: November 2024

About Disease Landscape & Forecast

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.



What are the sizes of the diagnosed, drug-treatable, and/or drug-treated populations?



What is the current treatment landscape?



What products are in development, and what is their launch potential and future positioning?



What is the market outlook of sales and patient share for the next 10 years?



What are the drivers and constraints of market growth, and what events will most impact the market's trajectory?



What unmet needs and opportunities exist?

Methodology and scope

Market forecast

- **Forecast:** Annualized drug-level sales and patient share of key breast cancer therapies from 2023-2033, segmented by brands/generics/biosimilars.
- **Epidemiology:** Diagnosed incidence of breast cancer by country; drug-treatable and drug-treated cases.
- **Market segmentations:** HR-positive / HER2-negative breast cancer: early stage (I-III) and metastatic (IV) first to sixth line; HER2-positive (HR-positive and HR-negative) breast cancer: early stage (I-III) and metastatic (IV) first to fifth line; triple-negative breast cancer: early stage (I-III) and metastatic (IV) first to fifth line.
- **Additional content:** Downloadable Excel files containing detailed forecast assumptions and visual outputs.

Primary market research

- Interviews with 25 thought-leading medical oncologists across the G7.
- Data and insights leveraged from 210 physician surveys conducted by Clarivate in breast cancer to model current and future market dynamics.

Geography



United States



EU5



Japan

Key therapies covered

Phase 3


- Gedatolisib (Celcuity)
- Datopotamab deruxtecan (Daiichi Sankyo / AstraZeneca)
- Camizestrant (AstraZeneca)
- Imlunestrant (Eli Lilly)
- Giredestrant (Roche / Genentech)
- Vepdegestrant (Arvinas / Pfizer)
- Sacituzumab tirumotecan (Merck KGaA)

Marketed

- Perjeta, Kadcyła, Phesgo, Itovebi (Roche / Genentech / Chugai)
- Enhertu (Daiichi Sankyo / AstraZeneca)
- Tukysa (Seagen)
- Ibrance (Pfizer)
- Kisqali (Novartis)
- Verzenio / Verzenios (Eli Lilly)
- Lynparza (AstraZeneca / Merck & Co.)
- Piqray (Novartis)
- Trodelvy (Gilead Sciences)
- Keytruda (Merck & Co.)
- Orserdu (Menarini)
- Truqap (AstraZeneca)

Report table of contents

1. **Executive Summary**
2. **Key Updates**
3. **Market Forecast**
 - Key takeaways
 - Market drivers and constraints
 - Segment-specific trends
5. **Epidemiology**
 - Key takeaways
 - Epidemiology populations
 - Diagnosed incident cases
 - Stage distribution of breast cancer.
 - Subpopulations: HR-positive / HER2-negative, HER2-positive, and triple-negative breast cancer.
 - Recurrent incident cases of breast cancer
 - Drug-treatable and drug-treated populations
6. **Current Treatment**
 - Key takeaways
 - Treatment for breast cancer
 - Key current therapies
7. **Emerging Therapies**
 - Key takeaways
 - Key emerging therapies
 - Unmet need in breast cancer
8. **Drug Pipeline** (powered by *Cortellis*)
9. **Appendix**



Report format



In-depth written analyses available on Clarivate's Insights Platform or as a PDF download



Succinct **Executive Summary** deck



Market Forecast Assumptions (flat data file providing comprehensive view of the 10-year, annualized, patient-based market forecast assumptions, including a detailed methodology)




Market Forecast Dashboard (interactive tool to help understand, interpret, explore, and visualize key outputs from the market forecast)

Sample content

Question answered

What are the expected sales of key drugs used to treat breast cancer in the G7 markets over the next 10 years?


SALES	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Sales	\$10,762.00	\$11,000.00	\$11,200.00	\$11,400.00	\$11,600.00	\$11,800.00	\$12,000.00	\$12,200.00	\$12,400.00	\$12,600.00	\$12,800.00
Total Breast Cancer	\$10,762.00	\$11,000.00	\$11,200.00	\$11,400.00	\$11,600.00	\$11,800.00	\$12,000.00	\$12,200.00	\$12,400.00	\$12,600.00	\$12,800.00
HER2-targeting agents	\$2,471.00	\$2,500.00	\$2,550.00	\$2,600.00	\$2,650.00	\$2,700.00	\$2,750.00	\$2,800.00	\$2,850.00	\$2,900.00	\$2,950.00
Trastuzumab emtansine	\$1,410.00	\$1,450.00	\$1,500.00	\$1,550.00	\$1,600.00	\$1,650.00	\$1,700.00	\$1,750.00	\$1,800.00	\$1,850.00	\$1,900.00
Brand	\$1,410.00	\$1,450.00	\$1,500.00	\$1,550.00	\$1,600.00	\$1,650.00	\$1,700.00	\$1,750.00	\$1,800.00	\$1,850.00	\$1,900.00
Biosimilar											
Trastuzumab derustecan	\$1,000.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00
Brand	\$1,000.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00
Generic											
DB-1303				\$100.00	\$200.00	\$300.00	\$400.00	\$500.00	\$600.00	\$700.00	\$800.00
Brand				\$100.00	\$200.00	\$300.00	\$400.00	\$500.00	\$600.00	\$700.00	\$800.00
Generic											
CDK4/6 inhibitors	\$8,291.00	\$8,500.00	\$8,650.00	\$8,800.00	\$8,950.00	\$9,100.00	\$9,250.00	\$9,400.00	\$9,550.00	\$9,700.00	\$9,850.00
Palbociclib	\$1,000.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00
Brand	\$1,000.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00	\$1,050.00
Generic											
Ribociclib	\$7,291.00	\$7,450.00	\$7,600.00	\$7,750.00	\$7,900.00	\$8,050.00	\$8,200.00	\$8,350.00	\$8,500.00	\$8,650.00	\$8,800.00
Brand	\$7,291.00	\$7,450.00	\$7,600.00	\$7,750.00	\$7,900.00	\$8,050.00	\$8,200.00	\$8,350.00	\$8,500.00	\$8,650.00	\$8,800.00
Generic											
Abemaciclib											
Brand											
Generic											
Atimociclib											
Brand											
Generic											
PI3K inhibitors											
Alpelisib											
Brand											
Generic											
Inavolisib											
Brand											
Generic											
PI3K / mTOR inhibitors											
Gedatolisib											
Brand											
Generic											
TROP2-targeting antibody-drug											
Sacituzumab govitecan											
Brand											
Generic											
Sacituzumab tirumotecan											
Brand											
Generic											
TROP-2 targeting agents											
Datopotamab derustecan											
Brand											
Generic											
Grand Total	\$10,762.00	\$11,000.00	\$11,200.00	\$11,400.00	\$11,600.00	\$11,800.00	\$12,000.00	\$12,200.00	\$12,400.00	\$12,600.00	\$12,800.00



Sample content

Question answered


What is the current treatment paradigm in breast cancer



Sample content

Question answered


When are the key novel therapies expected to launch for the breast cancer market over the next 10 years?



Sample content

Question answered

What clinical unmet needs remain unfulfilled and represent the top opportunities for drug developers?





About Clarivate

Disease Intelligence and Analytics

Disease intelligence you can trust



Size your market

Understand global and local markets, by gauging the size of the drug treatable population, where they're located, and how populations will change over time.



Identify unmet needs

Identify areas of unmet need and direct your clinical development strategy to the areas with the greatest opportunity.



Fuel successful market access

Optimize your market access strategy with brand-level insight regarding the impact of payer policy on physician prescribing behavior.



Assess and prioritize opportunities

Evaluate market potential for your assets – and those of your competitors – and optimize your strategy with indication-specific market intelligence combined with world-class epidemiology.



Understand the patient journey

Gain visibility into brand usage by line of therapy with RWD and uncover the 'why' behind treatment pathways and brand usage with in-depth coverage of physician perceptions on disease management.



Optimize your brand positioning

Analyze treatment pathways across highly dynamic oncology indications to support brand positioning, strategic planning, and business development.

Find out more

Learn more about how Clarivate can help you maximize your market share:
clarivate.com/products/biopharma/portfolio-strategy-business-development



Think forward™

Contact our experts today:
healthcare.support@clarivate.com
clarivate.com

About Clarivate

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

© 2024 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.